Neoantigen-Based Vaccination Unlocks Precision Immunotherapy in Fibrolamellar Carcinoma

For the vast majority of patients, primary liver tumours arise as a complication of chronic liver disease. Cirrhosis represents a recognised pre-neoplastic niche where hepatocyte transformation occurs in the context of progressive and often long-standing parenchymal inflammation.1